AU2014207420B2 - Evaluation and treatment of bradykinin-mediated disorders - Google Patents

Evaluation and treatment of bradykinin-mediated disorders Download PDF

Info

Publication number
AU2014207420B2
AU2014207420B2 AU2014207420A AU2014207420A AU2014207420B2 AU 2014207420 B2 AU2014207420 B2 AU 2014207420B2 AU 2014207420 A AU2014207420 A AU 2014207420A AU 2014207420 A AU2014207420 A AU 2014207420A AU 2014207420 B2 AU2014207420 B2 AU 2014207420B2
Authority
AU
Australia
Prior art keywords
gly
lys
thr
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014207420A
Other languages
English (en)
Other versions
AU2014207420A1 (en
Inventor
Burt Adelman
Yung CHYUNG
Greg Conley
Ryan Faucette
Jon A. Kenniston
Andrew Nixon
Daniel J. Sexton
Christopher Tenhoor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2014207420A1 publication Critical patent/AU2014207420A1/en
Application granted granted Critical
Publication of AU2014207420B2 publication Critical patent/AU2014207420B2/en
Priority to AU2018260845A priority Critical patent/AU2018260845B2/en
Priority to AU2020277178A priority patent/AU2020277178B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Priority to AU2024205664A priority patent/AU2024205664A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2014207420A 2013-01-20 2014-01-17 Evaluation and treatment of bradykinin-mediated disorders Active AU2014207420B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018260845A AU2018260845B2 (en) 2013-01-20 2018-11-07 Evaluation and treatment of bradykinin-mediated disorders
AU2020277178A AU2020277178B2 (en) 2013-01-20 2020-11-25 Evaluation and treatment of bradykinin-mediated disorders
AU2024205664A AU2024205664A1 (en) 2013-01-20 2024-08-09 Evaluation and treatment of bradykinin-mediated disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754607P 2013-01-20 2013-01-20
US61/754,607 2013-01-20
PCT/US2014/012107 WO2014113712A1 (en) 2013-01-20 2014-01-17 Evaluation and treatment of bradykinin-mediated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018260845A Division AU2018260845B2 (en) 2013-01-20 2018-11-07 Evaluation and treatment of bradykinin-mediated disorders

Publications (2)

Publication Number Publication Date
AU2014207420A1 AU2014207420A1 (en) 2015-07-02
AU2014207420B2 true AU2014207420B2 (en) 2018-08-09

Family

ID=51210106

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014207420A Active AU2014207420B2 (en) 2013-01-20 2014-01-17 Evaluation and treatment of bradykinin-mediated disorders
AU2018260845A Active AU2018260845B2 (en) 2013-01-20 2018-11-07 Evaluation and treatment of bradykinin-mediated disorders
AU2020277178A Active AU2020277178B2 (en) 2013-01-20 2020-11-25 Evaluation and treatment of bradykinin-mediated disorders
AU2024205664A Pending AU2024205664A1 (en) 2013-01-20 2024-08-09 Evaluation and treatment of bradykinin-mediated disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018260845A Active AU2018260845B2 (en) 2013-01-20 2018-11-07 Evaluation and treatment of bradykinin-mediated disorders
AU2020277178A Active AU2020277178B2 (en) 2013-01-20 2020-11-25 Evaluation and treatment of bradykinin-mediated disorders
AU2024205664A Pending AU2024205664A1 (en) 2013-01-20 2024-08-09 Evaluation and treatment of bradykinin-mediated disorders

Country Status (21)

Country Link
US (2) US11156612B2 (enExample)
EP (3) EP3456744B1 (enExample)
JP (4) JP6444315B2 (enExample)
KR (3) KR102381478B1 (enExample)
CN (2) CN111044725B (enExample)
AU (4) AU2014207420B2 (enExample)
CA (2) CA3209608A1 (enExample)
CY (1) CY1122164T1 (enExample)
DK (1) DK2948479T3 (enExample)
ES (1) ES2692408T3 (enExample)
HR (1) HRP20181734T1 (enExample)
HU (1) HUE041332T2 (enExample)
IL (2) IL273688B2 (enExample)
LT (1) LT2948479T (enExample)
PL (1) PL2948479T3 (enExample)
PT (1) PT2948479T (enExample)
RS (1) RS57890B1 (enExample)
SI (1) SI2948479T1 (enExample)
SM (1) SMT201800563T1 (enExample)
TR (1) TR201815856T4 (enExample)
WO (1) WO2014113712A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
EP2970502A4 (en) 2013-03-15 2016-11-30 Dyax Corp ANTI-PLASMA KALLIKREIN ANTIBODY
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US20180298110A1 (en) * 2015-03-30 2018-10-18 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
JP6903648B2 (ja) * 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ
CN116077648A (zh) * 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP3390439B1 (en) * 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
HRP20201131T1 (hr) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3513196A1 (en) * 2016-09-16 2019-07-24 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
MX2019002918A (es) * 2016-09-16 2019-07-18 Dyax Corp Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
WO2019165308A1 (en) * 2018-02-22 2019-08-29 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
JP2023521667A (ja) * 2020-04-04 2023-05-25 武田薬品工業株式会社 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) * 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993003748A1 (en) * 1991-08-13 1993-03-04 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2216651A4 (en) * 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
WO2009053050A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
AU2013205086A1 (en) * 2009-01-06 2013-05-16 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
CN102762203A (zh) 2009-12-18 2012-10-31 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂的前药
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2905545T3 (es) * 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2593121A2 (en) 2010-07-13 2013-05-22 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
AU2011336345B2 (en) 2010-12-02 2016-07-07 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
AU2012267546B2 (en) 2011-06-10 2015-12-24 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
US20140220552A1 (en) 2013-02-01 2014-08-07 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6903648B2 (ja) 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ

Also Published As

Publication number Publication date
AU2018260845A1 (en) 2018-11-22
CA2897336C (en) 2023-10-17
AU2020277178B2 (en) 2024-05-09
SI2948479T1 (sl) 2019-01-31
SMT201800563T1 (it) 2018-11-09
US20150362493A1 (en) 2015-12-17
IL273688A (en) 2020-05-31
IL273688B2 (en) 2024-12-01
JP6444315B2 (ja) 2018-12-26
EP3456744A1 (en) 2019-03-20
AU2020277178A1 (en) 2020-12-24
JP2022084648A (ja) 2022-06-07
KR102381478B1 (ko) 2022-04-01
KR102203880B1 (ko) 2021-01-15
DK2948479T3 (en) 2018-11-26
RS57890B1 (sr) 2019-01-31
CN111044725B (zh) 2024-03-29
CY1122164T1 (el) 2020-07-31
IL239428A0 (en) 2015-07-30
JP6772237B2 (ja) 2020-10-21
LT2948479T (lt) 2018-11-26
CN111044725A (zh) 2020-04-21
PL2948479T3 (pl) 2019-02-28
EP2948479A1 (en) 2015-12-02
IL273688B1 (en) 2024-08-01
KR20220045992A (ko) 2022-04-13
ES2692408T3 (es) 2018-12-03
BR112015016231A2 (pt) 2017-07-11
PT2948479T (pt) 2018-11-14
CN105073778B (zh) 2020-01-10
US20220170936A1 (en) 2022-06-02
CA3209608A1 (en) 2014-07-24
AU2014207420A1 (en) 2015-07-02
CN105073778A (zh) 2015-11-18
JP2019055975A (ja) 2019-04-11
EP2948479A4 (en) 2016-07-20
CA2897336A1 (en) 2014-07-24
EP4234583A2 (en) 2023-08-30
KR20210007044A (ko) 2021-01-19
EP4234583A3 (en) 2024-01-24
WO2014113712A1 (en) 2014-07-24
HK1215266A1 (en) 2016-08-19
EP3456744B1 (en) 2023-03-29
BR112015016231A8 (pt) 2019-10-29
AU2024205664A1 (en) 2024-08-29
KR102523810B1 (ko) 2023-04-21
JP7496380B2 (ja) 2024-06-06
KR20150106006A (ko) 2015-09-18
HUE041332T2 (hu) 2019-05-28
US11156612B2 (en) 2021-10-26
AU2018260845B2 (en) 2020-09-03
JP2021008483A (ja) 2021-01-28
HRP20181734T1 (hr) 2018-12-28
TR201815856T4 (tr) 2018-11-21
JP2016511823A (ja) 2016-04-21
EP2948479B1 (en) 2018-08-01
IL239428B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
AU2020277178B2 (en) Evaluation and treatment of bradykinin-mediated disorders
EP2946206B1 (en) Evaluation, assays and treatment of pkal-mediated disorders
HK40096540A (en) Evaluation and treatment of bradykinin-mediated disorders
HK40006266A (en) Evaluation and treatment of bradykinin-mediated disorders
HK40006266B (en) Evaluation and treatment of bradykinin-mediated disorders
HK1215266B (en) Evaluation and treatment of bradykinin-mediated disorders
HK40007358A (en) Treatment of pkal-mediated disorders
BR112015016231B1 (pt) Método para identificar um sujeito em risco de ou tendo um distúrbio mediado por pkal, método para avaliar um tratamento de um distúrbio mediado por pkal em um sujeito, método para tratar uma doença mediada por pkal, composição farmacêutica para uso notratamento de uma doença mediada por pkal de um sujeito e método para determinar um valor de cininogênio clivado, cininogênio intacto ou ambos, em uma amostra
HK1214361B (en) Evaluation, assays and treatment of pkal-mediated disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): DYAX CORP.